Document:

Forbearance Agreement, dated as of September 30, 2010

 EXHIBIT 10.1 

FORBEARANCE AGREEMENT 

This FORBEARANCE AGREEMENT (this “Agreement”) is made and entered into as of September 30, 2010, by and
among ANGIOTECH PHARMACEUTICALS, INC., a corporation organized under the laws of the Province of British Columbia, Canada (“Parent”), each of Parent’s Subsidiaries identified as a “Borrower” on the signature
pages hereof (such Subsidiaries, each a “Borrower”, and collectively, jointly and severally, the “Borrowers”), the Lenders (as defined in the Credit Agreement referred to below) listed on the signature pages hereof
and WELLS FARGO CAPITAL FINANCE, LLC, a Delaware limited liability company formerly known as Wells Fargo Foothill, LLC, in its capacity as arranger and administrative agent (“Agent”) for the Lenders. 

WITNESSETH: 

WHEREAS, the Parent, the Borrowers, the Lenders and Agent are parties to that certain Credit Agreement, dated as of February 27,
2009 (as amended, supplemented or modified, the “Credit Agreement”); 
 WHEREAS, the Parent has notified Agent
and the Lenders that it does not intend to make the interest payment due October 1, 2010 on the Senior Subordinated Notes on a timely basis, which event would constitute a Default under Section 8.7 of the Credit Agreement and an Event of
Default under Section 8.13 of the Credit Agreement (the “Prospective Default”); 
 WHEREAS, under the
terms of the Credit Agreement, it is a condition to the applicable Lenders continuing to make Advances to the Borrowers that, among other things, no Default or Event of Default shall have occurred and be continuing on the date of such extension of
credit, nor shall result from the making thereof; and 
 WHEREAS, the Borrowers have requested that the Lenders with a Revolver
Commitment continue to fund requested Advances notwithstanding the existence of the Prospective Default and that Agent and the Lenders forbear from exercising their rights and remedies under the Credit Agreement, the other Loan Documents and
applicable law, all of which Agent and the Lenders are willing to do on the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the agreements and provisions herein contained, the parties hereto do hereby agree as follows:

 Section 1. Definitions. Any capitalized terms used but not otherwise defined herein shall have the meanings
ascribed to such terms in the Credit Agreement. 
 Section 2. Acknowledgments. Each of the above recitals is
expressly incorporated herein and is represented by the Parent and each Borrower to be true and correct. Without limiting the foregoing, the Parent and each Borrower acknowledges and agrees that, but for the effectiveness of this Agreement,
(a) the Prospective Default would occur and be continuing, (b) the existence 

 
of the Prospective Default would relieve the applicable members of the Lender Group from any obligation to extend any Advance or provide any other credit under the Credit Agreement or any other
Loan Documents, and (c) the existence of the Prospective Default would permit the Lender Group, as applicable, to, among other things, (i) suspend or terminate any commitment to provide Advances or provide any other credit under the Credit
Agreement or any other Loan Document, (ii) accelerate all or any portion of the Obligations, (iii) charge interest on any and all of the Obligations at the default rate applicable under the Section 2.6(c) of the Credit Agreement,
(iv) commence any legal or other action to collect any or all of the Obligations from the Borrowers, any other Loan Party and/or any Collateral, (v) foreclose or otherwise realize on any or all of the Collateral, and/or appropriate,
set-off and apply to the payment of any or all of the Obligations, any or all of the Collateral, and/or (vi) take any other enforcement action or otherwise exercise any or all rights and remedies provided for by any or all of the Credit
Agreement, the other Loan Documents or applicable law. 
 Section 3. Reaffirmation of Obligations, etc. The
Parent and each Borrower hereby acknowledges that the Loan Documents and the Obligations constitute the valid and binding obligations of each such Person enforceable against each such Person in accordance with their respective terms, and the Parent
and each Borrower hereby reaffirms its obligations under the Loan Documents. Agent’s and the Lenders’ entry into this Agreement or any of the documents referenced herein, their negotiations with any party with respect to any Loan Document,
their conduct of any analysis or investigation of the operations of the Parent, any Borrower, any Collateral or any Loan Document, their acceptance of any payment from the Parent, any Borrower or any other party of any payments made prior to or
after the date hereof, their making of any Advance or other extension of credit prior to or after the date hereof, or any other action or failure to act on the part of any member of the Lender Group shall not, except as expressly provided herein,
(a) constitute a modification of any Loan Document, (b) constitute a waiver of any condition, Default or Event of Default under the Credit Agreement, including, without limitation, the Prospective Default, or a waiver of any term or
provision of any Loan Document, (c) excuse any Loan Party from any of its obligations under any of the Loan Documents, or (d) toll the running of any time periods applicable to any rights and remedies of the Lender Group or any member
thereof, including, without limitation, any grace periods with respect to any Defaults under the Loan Documents or otherwise. The Parent and each Borrower agrees that it will not assert laches, waiver or any other defense to the enforcement of any
of the Loan Documents based upon any agreement or action by any member of the Lender Group referenced in, set forth in or contemplated by, this Agreement. 

Section 4. Forbearance and Agreement to Continue to Lend. During the Forbearance Period (as defined below): (a) the
Lender Group shall not take any action or commence any proceedings with respect to the enforcement of any of its rights or remedies under the Loan Documents or applicable law as a result of the Prospective Default; and (b) the Lenders with
Revolver Commitments shall, notwithstanding the existence of the Prospective Default, continue to fund Advances (and extend any other credit provided for under the Credit Agreement) but subject to all other applicable provisions of the Credit
Agreement. 

 “Forbearance Period” shall mean the period commencing upon the Effective Date and
continuing until the earliest to occur of: (i) other than the Prospective Default, any Default or any Event of Default (including any other Default or Event of Default arising from the failure to make the interest payment due October 1,
2010 on the Senior Subordinated Notes, including, without limitation, the acceleration of all or any of the Senior Notes or the taking of any action by any Indenture Trustee or any holder of any of the Senior Notes to obtain payment of all or any of
the Senior Notes); (ii) any Material Adverse Change since the date of this Agreement and (iii) the Specified Date. 

“Specified Date” shall mean October 31, 2010; provided, that if the Senior Subordinated Notes Indenture is amended, pursuant
to a supplemental indenture that (x) is effective as to, and is binding and enforceable against, all holders of the Senior Subordinated Notes, and (y) extends the date on which the failure of the Parent to make the interest payment under
the Senior Subordinated Notes due on October 1, 2010 (the “Required Interest Payment Date”) becomes an “Event of Default” (as defined in the Senior Subordinated Notes Indenture) under the Senior Subordinated Notes
Indenture to a date that is more than 30 days following the Required Interest Payment Date (such date, the “Cure Period Termination Date”), the term “Specified Date” shall mean the Cure Period Termination Date;
provided, further, that in all events, and notwithstanding anything to the contrary contained herein, the “Specified Date” shall occur no later than November 30, 2010. 

Section 5. Rights Upon Termination of Forbearance Period. The Parent and each Borrower acknowledges and agrees that upon
the termination of the Forbearance Period as provided in Section 4 hereof, Agent, on behalf of the Lender Group, shall be entitled to exercise any or all of its remedies available under the Loan Documents or applicable law. 

Section 6. Representations and Warranties. In order to induce Agent and the Lenders to enter into this Agreement, the Parent and
each Borrower hereby represents and warrants that: 
 6.01 No Default. At and as of the date of this Agreement and
at and as of the Effective Date, other than the Prospective Default, no Default or Event of Default exists. 
 6.02
Representations and Warranties True and Correct. At and as of the date of this Agreement, and after giving effect to this Agreement, except for the existence of the Prospective Default, each of the representations and warranties contained
in the Credit Agreement and the other Loan Documents, is true and correct in all material respects (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by
materiality in the text thereof) (except to the extent that such representations and warranties relate solely to an earlier date, in which case they shall only be required to be true and correct in all material respects (except that such materiality
qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof) on such earlier date). 

6.03 Corporate Power, Etc. The Parent and each Borrower (a) has all requisite corporate power and authority to execute
and deliver this Agreement and to consummate the transactions contemplated hereby and (b) has taken all action, corporate or otherwise, necessary to authorize the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby. 

 6.04 Binding Effect. This Agreement has been duly executed and delivered by
the Parent and each Borrower and constitutes the legal, valid and binding obligation of each such Person, enforceable against each such Person in accordance with its terms, except as such enforceability may be limited by (a) applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, relating to or affecting the enforcement of creditors’ rights generally, and (b) the application of general principles of equity
(regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 6.05 No Duress.
This Agreement has been entered into without force or duress, of the free will of the Parent and each Borrower. The Parent’s and each Borrower’s decision to enter into this Agreement is a fully informed decision and such Person is aware of
all legal and other ramifications of such decision. 
 6.06 Counsel. The Parent and each Borrower has read and
understands this Agreement, has consulted with and been represented by legal counsel in connection herewith, and has been advised by its counsel of its rights and obligations hereunder and thereunder. 

Section 7. Conditions. This Agreement shall be effective as of September 30, 2010 (the “Effective Date”)
upon the fulfillment, in a manner satisfactory to Agent of all of the following conditions precedent set forth in this Section 7: 

7.01 Execution of Documents. Agent shall have received (a) a copy of this Agreement duly executed by Parent, the
Borrowers, Agent and the Lenders, and (b) a copy of the Consent and Affirmation set forth as Exhibit A to this Agreement duly executed by the Guarantors. 

7.02 Representations and Warranties. As of the Effective Date, the representations and warranties set forth in
Section 6 hereof shall be true and correct. 
 7.03 Forbearance Fee. The Borrowers shall have
paid to Agent, for its sole and separate account, a fully earned and nonrefundable forbearance fee equal to $50,000. 
 7.04
Compliance with Terms. The Loan Parties shall have complied in all respects with the terms hereof and of any other agreement, document, instrument or other writing to be delivered by any Loan Party in connection herewith. 

Section 8. Release and Covenant Not to Sue. 

8.01 The Parent and each Borrower hereby absolutely and unconditionally releases and forever discharges the Lender Group, and any
and all of their respective participants, parent corporations, subsidiary corporations, affiliated corporations, insurers, indemnitors, successors and assigns thereof, together with all of the present and former directors, officers, agents and
employees of any of the foregoing (each a “Released Party”), from any and all claims, demands 

 
or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise, which the Parent or any Borrower
has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising at any time on or prior to and including the date of this Agreement, whether such claims, demands and
causes of action are matured or unmatured or known or unknown, and in each case, arising for or on account of, in relation to, or in any way in connection with, any of the Credit Agreement, any other Loan Document and/or the transactions thereunder
or related thereto. It is the intention of the Parent and each Borrower in providing this release that the same shall be effective as a bar to each and every claim, demand and cause of action specified, and in furtherance of this intention it waives
and relinquishes all rights and benefits under any applicable law, which provides that: 
 “A general release does not
extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him might have materially affected his settlement with the debtor.” 

8.02 The Parent and each Borrower acknowledges that it may hereafter discover facts different from or in addition to those now
known or believed to be true with respect to such claims, demands, or causes of action and agree that this instrument shall be and remain effective in all respects notwithstanding any such differences or additional facts. The Parent and each
Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted,
prosecuted or attempted in breach of the provisions of such release. 
 8.03 The Parent and each Borrower, on behalf of
itself and its successors, assigns, and other legal representatives, hereby absolutely, unconditionally and irrevocably, covenants and agrees with and in favor of each Released Party above that it will not sue (at law, in equity, in any regulatory
proceeding or otherwise) any Released Party on the basis of any claim released, remised and discharged by the Parent or such Borrower pursuant to the above release. If the Parent, any Borrower or any of its successors, assigns or other legal
representations violates the foregoing covenant, the Parent and each Borrower, for itself and its successors, assigns and legal representatives, agrees, jointly and severally, to pay, in addition to such other damages as any Released Party may
sustain as a result of such violation, all attorneys’ fees and costs incurred by such Released Party as a result of such violation. 

Section 9. Miscellaneous. 

9.01 Continuing Effect. Except as specifically provided herein, the Credit Agreement and the other Loan Documents shall
remain in full force and effect in accordance with their respective terms and are hereby ratified and confirmed in all respects. 

9.02 No Waiver. This Agreement is limited as specified and the execution, delivery and effectiveness of this Agreement
shall not operate as a modification, acceptance or waiver of any provision of the Credit Agreement or any other Loan Document, except as specifically set forth herein. 

 9.03 References. 

(a) From and after the Effective Date, the Credit Agreement, the other Loan Documents and all agreements, instruments and documents
executed and delivered in connection with any of the foregoing shall each be deemed modified hereby to the extent necessary, if any, to give effect to the provisions of this Agreement. 

(b) From and after the Effective Date, (i) all references in the Credit Agreement to “this Agreement”,
“hereto”, “hereof”, “hereunder” or words of like import referring to the Credit Agreement shall mean the Credit Agreement as modified hereby and (ii) all references in the Credit Agreement, the other Loan Documents
or any other agreement, instrument or document executed and delivered in connection therewith to the “Credit Agreement”, “thereto”, “thereof”, “thereunder” or words of like import referring to the Credit
Agreement shall mean the Credit Agreement as modified hereby. 
 9.04 Governing Law. THIS AGREEMENT SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 9.05 Severability. The
provisions of this Agreement are severable, and if any clause or provision shall be held invalid or unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part
thereof, in such jurisdiction and shall not in any manner affect such clause or provision in any other jurisdiction, or any other clause or provision in this Agreement in any jurisdiction. 

9.06 Counterparts. This Agreement may be executed in any number of counterparts, each of which counterparts when executed
and delivered shall be an original, but all of which shall together constitute one and the same instrument. A complete set of counterparts shall be lodged with the Borrowers and Agent. 

9.07 Headings. Section headings in this Agreement are included herein for convenience of reference only and shall not
constitute a part of this Agreement for any other purpose. 
 9.08 Binding Effect; Assignment. This Agreement
shall be binding upon and inure to the benefit of the Parent, the Borrowers, the Lenders and Agent and their respective successors and assigns; provided, however, that no rights or obligations of the Parent or any Borrower under this
Agreement shall be assigned or delegated without the prior written consent of Agent. 
 9.09 Expenses. The
Borrowers agree to pay Agent upon demand for all Lender Group Expenses incurred by Agent in connection with the preparation, negotiation and execution of this Agreement and any document required to be furnished herewith. 

9.10 Submission of Agreement. The submission of this Agreement to the parties or their agents or attorneys for
review or signature does not constitute a commitment by Agent or any Lender to take or refrain from taking any action contemplated hereby and this Agreement shall have no binding force or effect until all of the conditions to the effectiveness of
this Agreement have been satisfied as set forth herein. 

 9.11 Modification. This Agreement may not be amended, waived or
modified in any manner without the written consent of the party against whom the amendment, waiver or modification is sought to be enforced. 

[Signature pages follow] 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
respective officers thereunto duly authorized, as of the date first above written. 
  

			
	 ANGIOTECH PHARMACEUTICALS, INC.,

as Parent

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	Chief Financial Officer
	
	 AFMEDICA, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 ANGIOTECH AMERICA, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 ANGIOTECH BIOCOATINGS CORP.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President

			
	 ANGIOTECH CAPITAL, LLC,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 ANGIOTECH PHARMACEUTICALS (US), INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 B.G. SULZLE, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 MANAN MEDICAL PRODUCTS, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 MEDICAL DEVICE TECHNOLOGIES, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President

			
	 NEUCOLL, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 QUILL MEDICAL, INC.,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 SURGICAL SPECIALTIES CORPORATION,

as a Borrower

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President

			
	 WELLS FARGO CAPITAL FINANCE, LLC,

as Agent and as a Lender

		
	By:	 	 /s/ Dennis J. Rebman

	Title:	 	Vice President

 CONSENT AND REAFFIRMATION 

In connection with the foregoing Forbearance Agreement (the “Agreement”), each of the undersigned, being a Guarantor (as
defined in the Credit Agreement referenced in the Agreement) under the Guaranty (as defined in the Credit Agreement referenced in the Agreement), hereby (i) acknowledges and agrees to the terms of the Agreement, (ii) makes each
acknowledgment of the Parent and the Borrowers set forth in Section 2 of the Agreement and agrees that each such acknowledgment of the Parent and the Borrowers is binding upon such Guarantor, and (iii) confirms and agrees that its
Guaranty is and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects except that, upon the effectiveness of, and on and after the date of the Agreement, each reference in such Guaranty to the Credit
Agreement (as defined in the Agreement), “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as modified by the Agreement. Although Agent and
the Lenders have informed the Guarantors of the matters set forth above, and each Guarantor has acknowledged the same, each Guarantor understands and agrees that neither the Lender Group nor the Bank Product Providers have any duty under the Credit
Agreement, any Guaranty or any other agreement with any Guarantor to so notify any Guarantor or to seek such an acknowledgement, and nothing contained herein is intended to or shall create such a duty as to any transaction hereafter. 

Each Guarantor hereby absolutely and unconditionally releases and forever discharges each Released Party (as defined in the Agreement),
from any and all claims, demands or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise, which such Guarantor has had, now has or has made
claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising at any time on or prior to and including the date of the Agreement, whether such claims, demands and causes of action are matured
or unmatured or known or unknown, and in each case, arising for or on account of, in relation to, or in any way in connection with, any of the Credit Agreement, any Guaranty, any other Loan Document and/or the transactions thereunder or related
thereto. It is the intention of each Guarantor in providing this release that the same shall be effective as a bar to each and every claim, demand and cause of action specified, and in furtherance of this intention it waives and relinquishes all
rights and benefits under any applicable law, which provides that: 
 “A general release does not extend to claims which the
creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him might have materially affected his settlement with the debtor.” 

Each Guarantor acknowledges that it may hereafter discover facts different from or in addition to those now known or believed to be true
with respect to such claims, demands, or causes of action and agree that this instrument shall be and remain effective in all respects notwithstanding any such differences or additional facts. Each Guarantor understands, acknowledges and agrees that
the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in

 
breach of the provisions of such release. Each Guarantor, on behalf of itself and its successors, assigns, and other legal representatives, hereby absolutely, unconditionally and irrevocably,
covenants and agrees with and in favor of each Released Party above that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Released Party on the basis of any claim released, remised and discharged by such Guarantor
pursuant to the above release. If any Guarantor or any of its successors, assigns or other legal representations violates the foregoing covenant, such Guarantor, for itself and its successors, assigns and legal representatives, agrees to pay, in
addition to such other damages as any Released Party may sustain as a result of such violation, all attorneys’ fees and costs incurred by such Released Party as a result of such violation. 

[Remainder of this page intentionally left blank.] 

 IN WITNESS WHEREOF, each Guarantor has executed this Consent and Reaffirmation on and as of
the date of the Agreement. 
  

			
	 ANGIOTECH PHARMACEUTICALS, INC.,

a corporation organized under the laws of the Province of British Columbia, Canada

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	Chief Financial Officer
	
	 0741693 B.C. LTD., 

a corporation organized under the laws of the Province of British Columbia, Canada

		
	By:	 	 /s/ Jay Dent

	Title:	 	Jay Dent
		 	Director
	
	 ANGIOTECH FLORIDA HOLDINGS, INC.,

a Delaware corporation

		
	By:	 	 /s/ K. Thomas Bailey

	Title:	 	K. Thomas Bailey
		 	President
	
	 ANGIOTECH INTERNATIONAL HOLDINGS, CORP., 

a corporation organized under the laws of the Province of Nova Scotia, Canada

		
	By:	 	 /s/ Jay Dent

	Title:	 	Jay Dent
		 	DirectorForm of U.S. Director Indemnification Agreement

 EXHIBIT 10.2 

INDEMNIFICATION AGREEMENT 

This Agreement dated September 28, 2010 

BETWEEN: 

¿, of ¿ 

(“Indemnitee”) 
 AND:

 ANGIOTECH PHARMACEUTICALS, INC., 

a corporation incorporated under the laws of British Columbia 

(“Angiotech”) 

BACKGROUND 
  

	A.	The Indemnitee is a director of Angiotech. 

  

	B.	Subject to the Business Corporations Act (British Columbia), Angiotech’s articles: 

 

	 	(a)	require Angiotech to indemnify the Indemnitee for certain liabilities and expenses that may be incurred by the Indemnitee by reason of the Indemnitee being a director
of Angiotech, as specified in Article 21.2, and deem the Indemnitee to have contracted with Angiotech on the terms of the indemnity contained in Article 21.2; and 

 

	 	(b)	authorize Angiotech to indemnify the Indemnitee for other liabilities and expenses that may be incurred by the Indemnitee by reason of the Indemnitee being a director,
officer, or employee of Angiotech, or of an affiliate or subsidiary of Angiotech, or of any other entity at Angiotech’s request. 

  

	C.	Angiotech and the Indemnitee wish to enter into an agreement: 

  

	 	(a)	to better define their respective rights and obligations in relation to the requirement to indemnify the Indemnitee under Article 21.2, and under the contract that is
deemed to exist between the Indemnitee and Angiotech under Article 21.2; and 

  

	 	(b)	to further require Angiotech to indemnify the Indemnitee in certain other circumstances for liabilities and expenses that the Indemnitee may incur by reason of the
Indemnitee being a director, officer, or employee of Angiotech, or of an affiliate or subsidiary of Angiotech, or of any other entity at Angiotech’s request, in accordance with this Agreement. 

 AGREEMENTS 

For good and valuable consideration, the receipt and sufficiency of which each party acknowledges, the parties agree as follows:

  

	1.	DEFINITIONS 

  

	1.1	In this Agreement: 

  

	 	(a)	“Act” means the Business Corporations Act (British Columbia), as amended from time to time, or any successor legislation;

  

	 	(b)	“Arbitration Act” means the International Commercial Arbitration Act (British Columbia), as amended from time to time, or any successor
legislation; 

  

	 	(c)	“Article 21.2” means Article 21.2 of Angiotech’s articles, as amended from time to time, or any successor provision of Angiotech’s articles, and
includes the contract that is deemed to exist between the Indemnitee and Angiotech under Article 21.2; 

  

	 	(d)	“Associated Corporation” means 

  

	 	(i)	a corporation that is or was an affiliate or subsidiary of Angiotech, at a time when the Indemnitee is or was a director, officer, or employee of the corporation,

  

	 	(ii)	another corporation of which the Indemnitee is or has been, at Angiotech’s request, a director, officer, or employee, or 

 

	 	(iii)	a partnership, trust, joint venture, or other unincorporated entity of which the Indemnitee holds or has held, at Angiotech’s request, a position equivalent to
that of a director or officer, or is or has been, at Angiotech’s request, an employee; 

  

	 	(e)	“Court” means the Supreme Court of British Columbia; 

  

	 	(f)	“Eligible Penalty” means a judgment, penalty, or fine awarded or imposed in, or an amount paid in settlement of, an Eligible Proceeding;

  

	 	(g)	“Eligible Proceeding” means a Proceeding in which the Indemnitee, or any of the Indemnitee’s heirs, successors, or personal or other legal
representatives 

  

	 	(i)	is or may be joined as a party, or 

  

	 	(ii)	is or may be liable for or in respect of a judgment, penalty, or fine in, or Expenses related to, the Proceeding, 

 

 2 

 by reason of the Indemnitee being or having been a director, officer, or employee of, or
holding or having held a position equivalent to that of a director or officer of, Angiotech or an Associated Corporation; 
  

	 	(h)	“Expenses” includes costs, charges, and expenses, including legal and other fees, but does not include judgments, penalties, fines, or amounts paid in
settlement of a Proceeding; 

  

	 	(i)	“Indemnitee” includes, except in paragraphs 1.1(d) and (g), 2.6, 3.1(c) and (d), 6.1 and 7.1, both the Indemnitee and the Indemnitee’s heirs, successors,
and personal or other legal representatives, but does not include anyone else; 

  

	 	(j)	“Insurers” means Chartis (formerly AIG Commercial Insurance Company of Canada), Lloyd’s Underwriters, XL Insurance Company Limited, Lloyd’s
Underwriters and Liberty International Underwriters, a division of Liberty Mutual Insurance Company, or an entity issuing a successor to a Policy in accordance with this Agreement; 

 

	 	(k)	“Policies” means the following directors’ and officers’ insurance policies issued by the Insurers and any successor to such policies entered into by
Angiotech: 

  

	 	(i)	Chartis (formerly AIG Commercial Insurance Company of Canada) executive and organization liability insurance policy no. 01-304-79-93; 

 

	 	(ii)	Lloyd’s Underwriters excess directors and officers and company reimbursement indemnity contract no. ZA042009 (1); 

 

	 	(iii)	XL Insurance Company Limited policy no. ELU114240-09; 

  

	 	(iv)	Lloyd’s Underwriters excess directors and officers and company reimbursement indemnity contract no. ZA042109 (1); and 

 

	 	(v)	Liberty International Underwriters, a division of Liberty Mutual Insurance Company, excess DIC side-A only executive advantage insurance policy no. DOCG782748002; and

  

	 	(l)	“Proceeding” includes any legal proceeding or investigative action, whether current, threatened, pending, or completed. 

 

	2.	INDEMNIFICATION 

 2.1 Subject to the
provisions of this Agreement, Angiotech will, to the fullest extent permitted by law: 
  

	 	(a)	indemnify and save harmless the Indemnitee from and against any and all Eligible Penalties for which the Indemnitee is or may be liable; and 

 

 3 

	 	(b)	after the final disposition of an Eligible Proceeding, pay the Expenses actually and reasonably incurred by the Indemnitee in respect of that Eligible Proceeding.

 2.2 Subject to paragraphs 3.3 and 3.4, at the request of the Indemnitee, Angiotech will pay Expenses actually and reasonably
incurred by the Indemnitee in respect of an Eligible Proceeding as those Expenses are incurred, in advance of the final disposition of the Eligible Proceeding. For greater certainty: 

 

	 	(a)	the Indemnitee will not be required to first pay such Expenses and then seek reimbursement from Angiotech; and 

 

	 	(b)	Angiotech will, at the Indemnitee’s request, pay such Expenses directly upon the Indemnitee providing receipts, statements of account, or other supporting
documentation that Angiotech may reasonably require. 

 2.3 If a claim for indemnification or payment of Expenses under paragraph
2.1 or 2.2 is not paid in full by Angiotech within 30 days after the Indemnitee delivers the claim, in writing, to Angiotech: 
  

	 	(a)	the Indemnitee may, at any time thereafter, commence dispute resolution under Part 11 to recover the unpaid amount of the claim; and 

 

	 	(b)	if the Indemnitee is wholly or substantially successful on the merits of the claim, Angiotech will also pay all Expenses actually and reasonably incurred by the
Indemnitee to pursue the claim under Part 11, unless an arbitrator under Part 11 orders otherwise. 

 2.4 If Court or
other approval is required in connection with any indemnification obligation of Angiotech under this Agreement, Angiotech will use reasonable efforts to promptly obtain that approval. 

2.5 The discharge by Angiotech of its obligations under this Agreement (to the extent permitted by law) will fully satisfy any rights the Indemnitee may
have under Article 21.2, and discharge any obligations Angiotech may have under Article 21.2, with respect to any Proceeding, including any claim the Indemnitee may have under Article 21.2 for indemnification from and against, or payment of, any
judgment, penalty, fine, costs, charges, or expenses, or any other liability whatsoever, that may be incurred in, or in relation to, any Proceeding. 

2.6 This Agreement is effective as of the date the Indemnitee first became a director or officer, or began to hold a position equivalent to that of a
director or officer, of Angiotech or any Associated Corporation, and will continue in effect after the Indemnitee ceases to be a director or officer, or to hold a position equivalent to that of a director or officer, of Angiotech or any Associated
Corporation. 
  

 4 

	3.	LIMITATIONS AND CONDITIONS 

 3.1 Subject
to paragraph 6.2, Angiotech will not indemnify the Indemnitee in respect of or in relation to any Eligible Proceeding or any Eligible Penalties incurred therein, or pay any Expenses of the Indemnitee in respect of or in relation to any Eligible
Proceeding: 
  

	 	(a)	if Angiotech is prohibited under the Act or any other applicable law from making such payments; 

 

	 	(b)	if the Eligible Proceeding is or was brought against the Indemnitee by or on behalf of Angiotech or an Associated Corporation; 

 

	 	(c)	if, in relation to the subject matter of the Eligible Proceeding, the Indemnitee did not act honestly and in good faith, with a view to the best interests of Angiotech
or of any applicable Associated Corporation, as the case may be; or 

  

	 	(d)	in the case of an Eligible Proceeding other than a civil proceeding, if the Indemnitee did not have reasonable grounds for believing that the Indemnitee’s conduct
in respect of which the Eligible Proceeding was brought was lawful. 

 3.2 Angiotech’s obligation under this Agreement to
indemnify the Indemnitee in respect of or in relation to any Eligible Proceeding or any Eligible Penalties incurred therein, or to pay any Expenses of the Indemnitee in respect of or in relation to any Eligible Proceeding, will be limited, and
Angiotech will not be required to make such payments, in the following circumstances: 
  

	 	(a)	if the Indemnitee makes an admission of liability or guilt or enters into a settlement with respect to the Eligible Proceeding without Angiotech’s consent contrary
to paragraph 4.2, to the extent any Eligible Penalties or Expenses are incurred as a result of that admission or settlement; 

  

	 	(b)	if, after Angiotech decides under paragraph 4.3 to assume and direct the carriage of the defence and handling of the Eligible Proceeding, the Indemnitee unreasonably
withholds consent to a request by Angiotech to enter into a settlement with respect to the Eligible Proceeding under paragraph 4.4(c), to the extent that any Expenses are incurred thereafter, and to the extent that any Eligible Penalties, or any
portion thereof, may not have been incurred if the Indemnitee had consented to such admission or settlement; 

  

	 	(c)	if, after Angiotech decides under paragraph 4.3 to assume and direct the carriage of the defence and handling of the Eligible Proceeding, the Indemnitee incurs any
Expenses in relation to the Eligible Proceeding that are not consented to or authorized by Angiotech or otherwise authorized under this Agreement, to the extent of such unauthorized Expenses; 

 

 5 

	 	(d)	to the extent that such indemnification has been provided, or payments made, to or on behalf of the Indemnitee by an insurer under a policy of insurance maintained by
Angiotech or an Associated Corporation; 

  

	 	(e)	to the extent that the Indemnitee may have become disentitled from receiving such indemnification from, or having such payments made by, an insurer under a policy of
insurance maintained by Angiotech or an Associated Corporation, as a result of the Indemnitee breaching any term or condition of the applicable policy of insurance contrary to paragraph 5.8, or exercising any right under the applicable policy of
insurance without Angiotech’s consent contrary to paragraph 5.9 or 

  

	 	(f)	to the extent that Angiotech or any Associated Corporation indemnifies or pays the Expenses of the Indemnitee in respect of or in relation to the Eligible Proceeding
other than under this Agreement. 

 3.3 The Indemnitee undertakes to repay Angiotech any amounts advanced under paragraph 2.2
if it is ultimately determined by an arbitrator under Part 11 or the Court that payment of those amounts was prohibited by section 163 of the Act. 

3.4 If the Indemnitee is required to repay Angiotech any amount under paragraph 3.3: 

 

	 	(a)	the Indemnitee will repay that amount to Angiotech forthwith; and 

  

	 	(b)	Angiotech will be entitled to set off any unpaid portion of that amount against any debt, liability, or amount that may be owing by Angiotech to the Indemnitee under
this Agreement or otherwise. 

 3.5 For the purpose of an arbitration under Part 11 or any other determination under this
Agreement: 
  

	 	(a)	there will be a rebuttable presumption that the Indemnitee has acted in good faith and with a view to the best interests of Angiotech and any applicable Associated
Corporation; 

  

	 	(b)	Angiotech will have the burden of proving: 

  

	 	(i)	that the Indemnitee did not act in good faith or with a view to the best interests of Angiotech or any applicable Associated Corporation, or did not otherwise meet the
standards of conduct which make it permissible under this Agreement, the Act, or other applicable law for Angiotech to indemnify the Indemnitee for any amount claimed; and 

 

	 	(ii)	that any Expenses claimed by the Indemnitee were not reasonably incurred; and 

 

	 	(c)	for greater certainty, Angiotech will bear the burden of proof described in subparagraph (b)(i) regardless of whether an Eligible Proceeding is terminated by judgment,
order, settlement, conviction, upon a plea of no contest or its equivalent, or otherwise. 

  

 6 

	4.	NOTICE, DEFENCE, AND SETTLEMENT OF ELIGIBLE PROCEEDING 

4.1 The Indemnitee will cooperate fully with Angiotech, and provide any information that Angiotech may require from time to time, and act with the utmost
good faith towards Angiotech, with respect to all matters under this Agreement. In particular, the Indemnitee will notify Angiotech forthwith of: 
  

	 	(a)	receiving notice of, or becoming aware of, any Eligible Proceeding (including a threatened Eligible Proceeding); 

 

	 	(b)	being served with any writ, statement of claim, notice of motion, indictment, or other document commencing or continuing any Eligible Proceeding; and

  

	 	(c)	all other steps taken in, or in relation to, any Eligible Proceeding; 

provided that any failure to give written notice or delay in giving notice under this paragraph will not disentitle the Indemnitee from receiving any
payment under this Agreement, except if and to the extent Angiotech is prejudiced by the failure or delay. 
 4.2 The Indemnitee will not make
any admission of liability or guilt, or enter into any settlement, with respect to any Eligible Proceeding without Angiotech’s prior written consent, which will not be unreasonably withheld. 

4.3 If Angiotech pays all Expenses actually and reasonably incurred by the Indemnitee in respect of an Eligible Proceeding within 30 days of any written
request by the Indemnitee under paragraph 2.2 (except as provided in paragraph 3.2 or 4.5), Angiotech may, at its option and subject to the provisions of any applicable policy of insurance, assume and direct the carriage of the defence and handling
of such Eligible Proceeding, to determine whether and in what manner such Eligible Proceeding will be defended, appealed, compromised, or settled, and, subject to paragraph 4.5, to select legal counsel, reasonably satisfactory to the Indemnitee, to
represent the Indemnitee. 
 4.4 If Angiotech assumes and directs the carriage of the defence and handling of an Eligible Proceeding under
paragraph 4.3: 
  

	 	(a)	the Indemnitee will cooperate fully with Angiotech and act with the utmost good faith towards Angiotech in all matters relating to such Eligible Proceeding;

  

	 	(b)	the Indemnitee will disclose to Angiotech any facts, information, or documents in the Indemnitee’s knowledge, possession, or control that may be relevant to the
defence and handling of the Eligible Proceeding, including, subject to paragraph 4.5, any legal or other professional advice obtained by the Indemnitee with respect to the defence and handling of the Eligible Proceeding;

  

 7 

	 	(c)	Angiotech will not make any admission of liability or guilt, or enter into any settlement on the Indemnitee’s behalf, without the Indemnitee’s prior written
consent, which will not be unreasonably withheld; and 

  

	 	(d)	Angiotech will indemnify the Indemnitee from and against all Eligible Penalties for which the Indemnitee is or may be liable in respect of the Eligible Proceeding, and
will pay any Expenses actually and reasonably incurred by the Indemnitee in respect of that Eligible Proceeding, except as provided in paragraph 3.1, 3.2 or 4.5. 

4.5 In any Eligible Proceeding, the Indemnitee may retain legal counsel, at the Indemnitee’s own expense, other than the counsel selected by
Angiotech under paragraph 4.3 to represent the Indemnitee, provided that the fees and disbursements of such other counsel will be paid by Angiotech if: 
  

	 	(a)	the Indemnitee and Angiotech mutually agree to the retainer of such other counsel; or 

 

	 	(b)	the parties to such Eligible Proceeding (including any added or interpleaded parties) include the Indemnitee and Angiotech (or any Associated Corporation), and
representation of both the Indemnitee and Angiotech (or the applicable Associated Corporation) by the same legal counsel is inappropriate or impracticable due to an actual or potential conflict between the interests of the Indemnitee and Angiotech
(or the applicable Associated Corporation). 

  

	5.	INSURANCE 

 5.1 Angiotech represents and
warrants to the Indemnitee that the Policies are in force unamended and Angiotech has paid all premiums owing under the Policies and is not otherwise in default under the terms of any Policy. To the best knowledge of Angiotech, any statements made
by or on behalf of Angiotech to an Insurer prior to the issuance of a Policy which form part of such Policy present a true and complete response to the questions posed by the Insurer as of the date such statements were made. 

5.2 Angiotech shall pay all premiums payable under the Policies and take all steps necessary to maintain the coverage provided under the Policies.

 5.3 So long as the Indemnitee is a director or officer of Angiotech or an Associated Corporation, Angiotech shall not seek to amend or
discontinue the Policies or allow the Policies to lapse without the Indemnitee’s prior written consent, acting reasonably, provided that such insurance is available on commercially reasonable terms (as determined by the board of directors in
its sole judgement). 
 5.4 So long as the Indemnitee is a director or officer of Angiotech or an Associated Corporation, upon the receipt of a
written request from the Indemnitee at any time during the term of this Agreement, Angiotech shall provide proof to the Indemnitee that all premiums payable by Angiotech in respect of the Policies have been paid. 

 

 8 

 5.5 In the event a Policy is discontinued for any reason, Angiotech shall purchase, maintain and administer,
or cause to be purchased, maintained and administered for a period of six years after such discontinuance, insurance for the benefit of the Indemnitee (the “Run-Off Coverage”), on such terms as Angiotech then maintains in existence for its
directors and officers, to the extent permitted by law and provided such Run-Off Coverage is available on commercially acceptable terms and premiums (as determined by the board of directors in its sole judgement). The Run-Off Coverage shall provide
coverage only in respect of events occurring prior to the discontinuance of the Policy. 
 5.6 Following the Indemnitee ceasing to be a director
or officer of Angiotech or an Associated Corporation, for any reason whatsoever, Angiotech shall continue to purchase and maintain directors’ and officers’ liability insurance, for the benefit of the Indemnitee such that the
Indemnitee’s insurance coverage is, at all times, the same as any insurance coverage Angiotech purchases and maintains for the benefit of its then current directors and officers, from time to time. Notwithstanding the foregoing, if
(i) liability insurance coverage for former directors and officers is no longer available or (ii) it is no longer industry practice among responsible companies to procure liability insurance for former directors and officers and the cost
to Angiotech to do so would be commercially unreasonable (as determined by the board of directors in its sole judgement), Angiotech shall be relieved of its obligation to procure liability insurance coverage for former directors and officers;
provided that Angiotech procures such level of insurance coverage, if any, as is available for former directors and officers at a commercially reasonable rate and adopts comparable measures to protect its former directors and officers in the
circumstances as are adopted by other responsible companies. The onus is on Angiotech to establish that the circumstances described in the previous sentence exist. 

5.7 If for any reason whatsoever, any directors’ and officers’ liability insurer asserts that the Indemnitee is subject to a deductible under
any existing or future directors’ and officers’ liability insurance purchased and maintained by Angiotech for the benefit of the Indemnitee, Angiotech shall pay the deductible for and on behalf of the Indemnitee. 

5.8 The Indemnitee will comply with all applicable obligations under any policy of insurance that may be maintained by Angiotech or by any Associated
Corporation under which coverage is provided or may be available for any Eligible Penalties or Expenses incurred with respect to an Eligible Proceeding. 

5.9 The Indemnitee will not, without the prior written consent of Angiotech, exercise any right under any policy of insurance referred to in paragraph
5.8 in any manner that may affect the provision or availability of coverage under the policy for any Eligible Penalties or Expenses incurred with respect to an Eligible Proceeding. 

 

	6.	OTHER RIGHTS OF THE INDEMNITEE 

 6.1
Subject to paragraph 2.5, the indemnification or payment of any Eligible Penalties or Expenses under this Agreement will not diminish any other rights to which the Indemnitee or the Indemnitee’s heirs, successors, or personal or other legal
representatives may be entitled under any provision of the Act or any other enactment, Angiotech’s articles, any applicable policy of 

 

 9 

 
insurance, guarantee, or third party indemnity, any vote of the shareholders of Angiotech, or otherwise, whether as to any matter arising out of the Indemnitee’s capacity as a director,
officer, or employee of Angiotech or an Associated Corporation, or as to any matter arising out of another capacity with Angiotech or an Associated Corporation while serving as a director, officer, or employee of Angiotech or an Associated
Corporation. 
 6.2 For greater certainty, this Agreement does not prevent either Angiotech or the Indemnitee from applying to the Court for an
order under section 164 of the Act. 
  

	7.	PAYMENT OF WITNESS EXPENSES 

 7.1 Despite
any other provision of this Agreement, if the Indemnitee is a witness or a participant other than a named party in an Eligible Proceeding by reason of the Indemnitee being or having been a director, officer, or employee of, or holding or having held
a position equivalent to that of a director or officer of, Angiotech or an Associated Corporation: 
  

	 	(a)	Angiotech will pay the out-of-pocket Expenses actually and reasonably incurred by or on behalf of the Indemnitee in connection therewith; and 

 

	 	(b)	if the Indemnitee is not currently an officer or employee of, and does not currently hold a position equivalent to that of an officer of, Angiotech or an Associated
Corporation, Angiotech will compensate the Indemnitee, at a rate equal to the then applicable board meeting fee received by directors of Angiotech, for each day of required attendance at or preparation for the Eligible Proceeding (prorated for
partial days). 

  

	8.	TAX ADJUSTMENT 

 8.1 If any payment under
this Agreement, including the payment of insurance premiums or any payment made by an insurer under an insurance policy, is or is deemed to be a taxable benefit or is otherwise subject to taxation, Angiotech will pay any amount necessary to ensure
that the amount received by or on behalf of the Indemnitee, after the payment of or withholding for tax, fully reimburses the Indemnitee for the actual amount of Eligible Penalties and Expenses to which the Indemnitee is entitled under this
Agreement, provided that such reimbursement will be net of any tax deductions that the Indemnitee successfully claims as a result of having incurred such Eligible Penalties and Expenses or receiving payment therefor. 

 

	9.	NOTICES 

 9.1 All notices and other
communications required or permitted to be given under this Agreement will be in writing, and will be delivered or sent by registered mail or overnight courier to the party entitled to receive them, as follows: 

 

					
	 (a)
	  	  
	  	
		  	  
	  	
		  	  
	  	

  

 10 

	 	(b)	ANGIOTECH PHARMACEUTICALS, INC. 

1618 Station Street 

Vancouver, BC V6A 1B6 

			
	 Attention:
	  	David D. McMasters,
		  	General Counsel and Senior Vice President, Legal

 9.2
Either party may notify the other in writing of a change of address to which notices will thereafter be given. 
  

	10.	SEVERABILITY AND WAIVER 

 10.1 Each
provision of this Agreement is a separate obligation and is severable from all other such obligations, and if any of them is held by an arbitrator under Part 11 or by a court to be invalid or unenforceable, this Agreement will be construed by
limiting, restricting, or reducing the application or scope of the applicable provision or provisions, to the extent necessary to comply with applicable law then in effect. 

10.2 In this Agreement: 
  

	 	(a)	a waiver of any provision of this Agreement will not be binding unless in writing and signed by both parties; 

 

	 	(b)	a failure to exercise or a delay in exercising any right or remedy under this Agreement will not be deemed to be a waiver of that right or remedy; and

  

	 	(c)	a waiver or excuse by either party of any default or breach by the other party of any provision of this Agreement will not waive that party’s rights in respect of
any continuing or subsequent default or breach, or affect the rights of that party in respect of any such continuing or subsequent default or breach. 

  

	11.	DISPUTE RESOLUTION 

 11.1 Before
initiating any legal proceedings, the parties will attempt to resolve all disputes concerning the interpretation, application, or enforcement of any term of this Agreement, any alleged breach of or non-compliance with this Agreement, or otherwise
arising out of or in connection with this Agreement, by mediated negotiation, and will use their best efforts to agree on a mediator and to resolve any disputes by mediation. 

11.2 If a dispute referred to in paragraph 11.1 cannot be resolved by mediation within 15 days after one of the parties notifies the other of an
intention to mediate the dispute, or if the parties are unable to agree to a mediator within 10 days of such notice, either party may give notice to the other party of its intention to refer the dispute to binding arbitration. 

11.3 A dispute that is referred to binding arbitration under paragraph 11.2 will be finally resolved by a single arbitrator under the Arbitration
Act. 
  

 11 

 11.4 If the parties are unable to agree on an arbitrator within 10 days of the notice referring the dispute
to arbitration, either party may make a request under the Arbitration Act for the Chief Justice of the Court to appoint an arbitrator, who may be of any nationality, but must be a member of the Law Society of British Columbia. 

11.5 The arbitration will be in Vancouver, British Columbia. 

11.6 The arbitrator will: 
  

	 	(a)	subject to the provisions of this Agreement, apply the International Commercial Arbitration Rules of Procedure of the British Columbia International Commercial
Arbitration Centre with any modifications as may be agreed to by the parties, or such other rules of procedure as may otherwise be agreed to by the parties; 

 

	 	(b)	not have the authority or jurisdiction to award: 

  

	 	(i)	punitive or aggravated damages, or damages for any intangible loss or injury, including damage or injury to reputation, or psychological damage or injury, or

  

	 	(ii)	injunctive relief, specific performance, or any other equitable remedy; 

  

	 	(c)	conduct the arbitration proceeding within 30 days of being appointed; and 

  

	 	(d)	render a decision within 30 days of the completion of the arbitration proceeding. 

11.7 Despite paragraph 11.3, either party may, before or after an arbitration has commenced, apply to the Court for interim relief under section 9 of the
Arbitration Act. 
  

	12.	GOVERNING LAW AND FORUM 

 12.1 This
Agreement is deemed to be made in British Columbia, and will be governed by and construed and interpreted in accordance with the laws of British Columbia and laws of Canada applicable therein. 

12.2 Subject to Part 11, each of the parties, by the execution and delivery of this Agreement, irrevocably and unconditionally attorns, submits to,
and accepts the jurisdiction of the courts of British Columbia with respect to any matter or thing arising out of or pertaining to this Agreement. 
  

	13.	INDEPENDENT LEGAL ADVICE 

 13.1
Angiotech’s lawyers prepared this Agreement. The Indemnitee was asked to obtain independent legal advice before signing this Agreement, and represents by signing it that such advice has been obtained. 

 

 12 

	14.	ENUREMENT AND ASSIGNMENT 

 14.1 This
Agreement will enure to the benefit of and be binding on the parties and their respective heirs, successors, personal or other legal representatives, and permitted assigns. 

14.2 The Indemnitee will not assign this Agreement without Angiotech’s prior written consent. 

 

	15.	INTERPRETATION 

 15.1 Any reference in
this Agreement to an enactment will be deemed to be a reference to such enactment as it may be amended or replaced from time to time, and any reference to a particular provision of an enactment will include a reference to an equivalent provision, if
the enactment is amended or replaced. 
 15.2 If Angiotech is continued, incorporated, amalgamated, arranged under, or otherwise becomes
governed by an enactment other than the Act, all references in this Agreement to the Act will be deemed to be references to such other enactment as it may be amended or replaced from time to time. 

15.3 Any rule of interpretation that any ambiguity is to be resolved against the drafting party is not applicable to this Agreement. 

 

	16.	ENTIRE AGREEMENT 

 16.1 This Agreement
will supersede and replace any and all prior agreements and discussions between the parties respecting its subject matter, and contains the entire agreement between the parties with respect to its subject matter (except any written agreement of
employment between Angiotech or an Associated Corporation and the Indemnitee, which, if in existence, will remain in effect except to the extent augmented or amended by this Agreement). 

16.2 No amendment or variation of the terms of this Agreement will be effective or binding unless in writing and signed by both parties. 

 

 13 

 TO EVIDENCE THEIR AGREEMENT the parties have executed this Agreement on the dates appearing below.

  

													
	 SIGNED, SEALED AND DELIVERED by

¿ in the presence of:
	    	 )
 )
	    		  		  	
		    	)	    		  		  	
	 	 	 	 	 	    	)	    		  		  	
	Signature of Witness	 		 		    	)	    		  		  	
		 		 		    	)	    		  	  
	  	
	 	 	 	 	 	    	)	    		  	¿	  	
	Print Name of Witness	 		 		    	)	    		  		  	
		 		 		    	)	    		  		  	
	 	 	 	 	 	    	)	    		  		  	
	Address of Witness	 		 		    	)	    		  		  	
		 		 		    	)	    		  		  	
	 	 	 	 	 	    	)	    		  		  	
	Occupation of Witness	 		 		    	)	    		  		  	
		 		 		    	)	    		  		  	
	     , 2010
	 	 	 	 	    	)	    		  		  	
	Date	 		 		    		    		  		  	

  

			
	ANGIOTECH PHARMACEUTICALS, INC.
		
	 By:
	 	
	
	  

	Authorized Signatory

  

							
	 Date:
	 	 	 	, 2010	 	 

  

 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]